OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use London and New York, NY

Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use

and New York, NY, August 6, 2024 - OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing

innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular

segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy,

announced today the grant of a key European Patent entitled:

"Compositions Comprising Chemerin Analogs and Methods of Use". The present disclosure that lists Raj Patil, Chief Scientific

Officer of OKYO Pharma as a joint Inventor, relates to novel OK-101 chemerin analogs for use in treating various diseases and conditions

including but not limited to, ocular inflammatory and pain conditions, strengthening the Company's intellectual property position

are delighted with the issuance of this European patent, which underscores the innovative nature of our OK-101 chemerin analogs and their

therapeutic potential. This milestone strengthens our intellectual property portfolio and positions OKYO Pharma for continued advancement

in addressing significant unmet medical needs," commented Dr. Gary S. Jacob, Ph.D., CEO of OKYO. "The issuance of this patent

further solidifies OKYO Pharma's commitment to advancing novel therapies that aim to improve outcomes for patients suffering from

ocular pain and inflammation. The company continues to explore strategic partnerships and collaborations to accelerate the development

and commercialization of its pipeline candidates."

is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of

the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide technology to produce a novel

long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing efficacy

signals in mouse models of dry eye disease and corneal neuropathic pain (NCP), respectively, and is designed to combat washout through

the inclusion of the lipid anchor built into the drug molecule to enhance the residence time of OK-101 within the ocular environment.

OK-101 recently showed statistical significance in multiple endpoints in a recently completed Phase 2, multi-center, double-blind, placebo-controlled

trial of OK-101 to treat DED.

Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of DED

and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel

molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 DED trial, OKYO also has plans underway

for the opening of a Phase 2 trial for OK-101 to treat NCP in patients with this debilitating condition. For further information, please

visit www.okyopharma.com.

statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather

are based on the Company's current expectations, estimates, and projections about its industry, its beliefs, and assumptions. Words

such as anticipates,' expects,' intends,' plans,' believes,' seeks,'

estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees

of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's

control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking

statements. These and additional risks and uncertainties are described more fully in the company's

filings with the SEC, including those factors identified as "Risk Factors" in our most recent Annual Report on Form 20-F,

for the fiscal year ended March 31, 2023. The Company cautions security holders and prospective security holders not to place

undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The

forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company

will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events,

circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate

regulatory authority.